Aura Biosciences, Inc. - 8-K Filing
Aura Biosciences reported Q1 2026 financial results, including $114.7 million in cash as of March 31, 2026, with an additional $280.8 million raised through a recent equity offering expected to fund operations into the second half of 2028. The company is advancing its Phase 3 CoMpass trial for bel-sar toward enrollment completion by mid-2026 and anticipates topline data in H2 2027, while also progressing trials in metastases to the choroid, ocular surface cancers, and bladder cancer. (Items: 2.02 Results of Operations and Financial Condition, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $AURA